Danaher (NYSE:DHR) Announces Earnings Results

Danaher (NYSE:DHR) announced its quarterly earnings data on Tuesday. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15, Briefing.com reports. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The firm had revenue of $5.74 billion for the quarter, compared to analysts’ expectations of $5.59 billion. During the same period last year, the business posted $2.05 earnings per share. The firm’s revenue for the quarter was down 2.9% on a year-over-year basis.

Danaher Stock Performance

Shares of NYSE DHR opened at $270.09 on Friday. The company has a quick ratio of 1.51, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. The business’s 50 day moving average is $254.99 and its two-hundred day moving average is $248.82. The company has a market cap of $195.06 billion, a P/E ratio of 45.78, a P/E/G ratio of 4.11 and a beta of 0.83. Danaher has a 12 month low of $182.09 and a 12 month high of $276.31.

Danaher Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.27 dividend. This represents a $1.08 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend is Friday, June 28th. Danaher’s dividend payout ratio is currently 18.31%.

Insiders Place Their Bets

In other news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Matthew Mcgrew sold 46,377 shares of Danaher stock in a transaction that occurred on Friday, May 10th. The stock was sold at an average price of $253.05, for a total value of $11,735,699.85. Following the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at approximately $7,441,441.35. The disclosure for this sale can be found here. Insiders have sold a total of 75,175 shares of company stock valued at $19,161,154 in the last three months. Company insiders own 11.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on DHR. Royal Bank of Canada increased their target price on Danaher from $297.00 to $300.00 and gave the stock an “outperform” rating in a research report on Wednesday. TD Cowen increased their target price on Danaher from $290.00 to $310.00 and gave the stock a “buy” rating in a research report on Wednesday. Barclays increased their target price on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research report on Wednesday. Robert W. Baird raised their price target on Danaher from $271.00 to $278.00 and gave the company an “outperform” rating in a report on Wednesday. Finally, Citigroup raised their price target on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a report on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat, Danaher currently has an average rating of “Moderate Buy” and a consensus target price of $276.88.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.